Interim report
Page 1
Date: 26 October 2026 To BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001 To National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex, Bandra (E) Mumbai-400051 Security Code: 540596 Symbol: ERIS SUBJECT: OUTCOME OF THE BOARD MEETING HELD TODAY, i.e., October 26, 2026 Dear Sir/Madam, Pursuant to Regulation 30 read with Regulation 5 2 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (“ LODR”) we hereby inform you that the Board of Directors of the Company, in their meeting held today, i.e., October 26, 2026 , inter alia , duly approved and took on record Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2026. In this regard, the following documents are enclosed: • A copy of the said financial results along with Limited review report pursuant to Regulation 33 and Regulation 52 of the SEBI Listing Regulations. The limited review reports are submitted with unmodified opinion(s) (free from any qualifications). • Details as per Regulation 52(4) of SEBI Listing Regulations. The meeting of the Board of Directors commenced at 11:00 A.M. and concluded at 01:40 P.M. This is for your information and record. Thanking You, For Eris Lifesciences Limited _________________________ Milind Talegaonkar Company Secretary & Compliance Officer Membership No: A26493
Page 2
Chartered Accountants Offices in Ahmedabad, Bengaluru, Chandigarh, Chennai, Dehradun, Goa, Gurugram, Hyderabad, Indore, Kochi, Kolkata, Mumbai, New Delhi, Noida and Pune Walker Chandiok & Co LLP is registered with limited liability with identification number AAC - 2085 and has its registered office at L-41, Connaught Circus, Outer Circle, New Delhi, 110001, India Year to Date Results of the Company pursuant to the Regulation 33 and Regulation 52 read with Regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) To the Board of Directors of Eris Lifesciences Limited 1. We have reviewed the accompanying statement of unaudited consolidated financial results of Eris Lifesciences Limited (refer Annexure 1 for the list of subsidiaries and joint venture included in the Statement) for the quarter ended 30 September 2026 and the consolidated year to date results for the period 1 April 2026 to 30 September 2026 being submitted by the Holding Company pursuant to the requirements of Regulation 33 and Regulation 52 read with Regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) . 2. the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standar principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 and Regulation 52 read with Regulation 63 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. Walker Chandiok & Co LLP Block No. D/15th Floor, Cabin No. A8 to A10 S.G Highway, Sarkhej Road, Ahmedabad-380015 Gujarat, India
Page 3
Chartered Accountants We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.4. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 and Regulation 52 read with Regulation 63 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.5. We did not review the interim financial results of 5 subsidiaries included in the Statement, whose 1,474.07 Crores as at 30 September 2026, and total 163.96 Crores 275.14 Crores, total net profit30.66 Crores 42.44 Crores, 30.07 Crores41.79 Crores for the quarter and six-month period ended on 30 September 2026, respectively, and net cash inflows of7.16 Crores for the period ended 30 September 2026, as considered in the Statement. The Statement also includes the 0.90 Crores1.30 Crores and total comprehensive loss 0.90 Crores1.30 Crores for the quarter and six-month period ended on 30 September 2026,respectively, as considered in the Statement, in respect of one joint venture, whose interim financial results have not been reviewed by us. These interim financial results have been reviewed by other auditors whose review reports have been furnished to us by the management, and our conclusion in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and joint venture is based solely on the review reports of such other auditors and the procedures performed by us as stated in paragraph 3 above.Our conclusion is not modified in respect of these matter with respect to our reliance on the work doneby and the reports of the other auditors.ForWalker Chandiok & Co LLPChartered AccountantsAshish GuptaPartnerMembership No.: 504662UDIN: 26504662LAQQUU4575Place: New DelhiDate: 26 October 2026
Page 4
Chartered Accountants Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 and Regulation 52 read with Regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) List of entities included in the Statement Holding Company Sr. No. Name of entity 1 Eris Lifesciences Limited Subsidiaries Sr. No. Name of entities 1 Eris Therapeutics Limited 2 Eris Oaknet Healthcare Private Limited (Step-down subsidiary) 3 Eris Healthcare Private Limited 4 Eris M. J. Biopharm Private Limited 5 Eris Pharmaceuticals Limited 6 Eris Bionxt Private Limited 7 Swiss Parenterals Limited Joint venture Sr. No. Name of entity 1 Levim Lifetech Private Limited
Page 5
In Eris EY Entrepreneur FROST & SULLIVAN of the year-2013 Best Practices-2013 Eris Lifesciences Limited Business today/YES bank Excellence Awards-2013 2013 Statement of Unaudited Consolidated Financial results for the quarter and half year ended September 30, 2026 Rs in Crore except per share data) Sr. No. Particulars For quarter ended For half year ended For year ended September 30, 2026 (Unaudited) June 30, 2026 (Unaudited) September 30, 2025 (Unaudited) September 30, 2026 (Unaudited) September 30, 2025 (Unaudited) March 31, 2026 (Audited) 1 Income Revenue from operations Sale of products 889.50 869.03 790.15 1,758.53 1,561.71 3,114.89 Other operating income 2.87 4.22 2.26 7.09 3.70 14.53 Total Revenue from operations 892.37 873.25 792.41 1,765.62 1,565.41 3,129.42 Other income 3.20 2.39 2.81 5.59 5.50 7.75 Total income 895.57 875.64 795.22 1,771.21 1,570.91 3,137.17 2 Expenses Cost of materials consumed 107.86 94.27 82.58 202.13 152.68 326.65 Purchase of stock-in-trade 167.72 131.12 146.09 298.84 250.35 490.56 Changes in inventories of finished goods, stock-in-trade and work-in-progress (49.85) 13.86 (26.26) (35.99) (15.98) (21.61) Employee benefits expense 149.19 153.42 137.45 302.61 281.88 556.81 Finance costs 46.42 46.65 49.55 93.07 98.23 192.67 Depreciation and amortisation expense 73.42 72.07 69.08 145.49 139.59 279.50 Other expenses 208.10 184.36 164.34 392.46 331.56 656.90 Total expenses 702.86 695.75 622.83 1,398.61 1,238.31 2,481.48 Profit before share of profit from investment in joint venture, exceptional item 3 and tax for the period / year (1-2) 192.71 179.89 172.39 372.60 332.60 655.69 4 Share of loss/ (profit) from investment in joint venture, net of tax 0.90 0.40 (0.28) 1.30 (1.17) (0.09) 5 Profit before exceptional Item and tax for the period / year (3-4) 191.81 179.49 172.67 371.30 333.77 655.78 6 Exceptional items (Refer note 5) 35.90 - - 35.90 - 17.24 7 Profit before tax for the period / year (5-6) 155.91 179.49 172.67 335.40 333.77 638.54 8 Tax Expense Current tax (64.78) 31.10 71.18 (33.68) 127.49 157.41 Deferred tax 33.55 5.07 (32.981 38.62 (53.291 (166.38) Total tax expense (Refer note 7) (31.23) 36.17 38.20 4.94 74.20 (8.97) 9 Net profit for the period / year (7-8) 187.14 143.32 134.47 330.46 259.57 647.51 Attributable to : - Owners of the Company 183.82 142.39 120.19 326.21 238.18 619.52 - Non controlling interest 3.32 0.93 14.28 4.25 21.39 27.99 10 Other comprehensive income/(loss) Items that will not be reclassified to gain or (loss) Re-measurement gains / (losses) on defined benefit plans 0.17 0.16 (0.84) 0.33 (1.68) 0.12 Income tax effect (0.04) (0.04) 0.27 (0.08) 0.54 0.22 Items that will be reclassified to profit or loss Net movement on effective portion of cash flow hedges (1.70) (0.03) - (1.73) - (2.42) Income tax effect 0.41 (0.03) 0.38 - 0.64 Other comprehensive income/(loss) for the period / year, net of tax (1.16) 0.06 (0.57) (1.10) (1.14) (1.44) Attributable to : - Owners of the Company (1.16) 0.06 (0.56) (1.10) (1.12) (1.47) - Non controlling interest 03_011 (0.021 0.03 11 Total comprehensive income Attributable to : - Owners of the Company 182.66 142.45 119.63 325.11 237.06 618.05 - Non controlling interest 3.32 0.93 14.27 4.25 21.37 28.02 Total comprehensive Income for the period / year (9+10) 185.98 143.38 133.90 329.36 258.43 646.07 12 Paid Up Equity Share Capital (Face Value of Rs 1 each) 13.87 13.86 13.62 13.87 13.62 13.85 13 Other Equity 3,888.82 14 Earnings Per Share (of Rs 1 each) (not annualised) : Basic 13.26 10.28 8.82 23.54 17.49 45.33 Diluted 13.25 10.26 8.81 23.53 17.46 45.26 Registered & Corporate Office: Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad - 380054 Phone: +91-79-69661000/1001 - Email: erisgerislifesciences.com - Web Site: www.eris.co.in CIN: L24232GJ2007PLC049867
Page 6
Statement of Consolidated Assets and Liabilities as at September 30, 2026 [Rs in Crorej Particulars As at September 30, 2026 M at March 31, 2026 (Unaudited) (Audited) L ASSETS : Non Current Assets (a) Property, plant and equipment 670.42 661.52 (b) Capital work in progress 394.94 171.47 (c) Right-of-use assets 45.21 46.85 (d) Goodwill 691.78 911.97 (e) Other intangible assets 3,455.78 3,567.22 (f) Intangible assets under development 6.05 - (g) Investments accounted using equity method (h) Financial assets (i) Investments 50.28 10.00 51.58 9.98 (ii) Loans 1.12 1.12 (iii) Other financial assets 11.40 9.83 (i) Non current tax assets (net) 51.46 40.66 (j) Deferred tax assets (net) 298.41 242.91 (k) Other assets 93.49 110.55 Total Non-current assets 5,780.34 5,825.66 Current assets (a) Inventories (b) Financial assets (i) Trade receivables 474.47 631.88 436.82 680.34 (ii) Cash and cash equivalents 238.09 54.74 (iii) Bank balances other than (iii) above 16.04 12.56 (iv) Loans 76.86 52.75 (v) Other financial assets 14.68 9.08 (c) Other assets 348.84 293.56 Total Current assets 1,800.86 1,539.85 TOTAL-ASSETS 7,581.20 7,365.51 II. EQUITY AND LIABILITIES • Equity (a) Equity share capital 13.87 13.85 (b) Other equity 4,130.47 3,888.82 Equity attributable to the owners of the company 4,144.34 3,902.67 (c) Non-controlling interest (2.76) (7.01) Total Equity 4,141.58 3,895.66 Non-current liabilities (a) Financial liabilities (i) Borrowings 427.46 955.83 (ii) Lease liabilities 37.59 40.19 (iii) Other financial liabilities 1.07 1.07 (b) Other liabilities 3.52 3.80 (c) Provisions 110.13 86.78 (d) Deferred tax liabilities (net) 178.71 305.08 Total Non-Current liabilities 738.411 1,392.75 Current liabilities (a) Financial Liabilities (i) Borrowings 1,954.34 1,353.85 (ii) Lease liabilities (iii) Trade payables i) Total outstanding dues of micro enterprises and small enterprises 10.11 32.76 8.75 8.76 ii) Total outstanding dues of creditors other than micro enterprises and small enterprises 422.98 320.89 (iv) Other financial liabilities 146.37 197.74 (b) Other liabilities 59.04 71.64 (c) Provisions 41.72 37.71 (d) Current tax liabilities (net) 13.82 77.76 Total Current liabilities 2,681.14 2,077.10 Total liabilities 3,439.62 3,469.85 TOTAL- EQUITY AND LIABILITIES 7,581.20 7,365.51
Page 7
Unaudited Statement of consolidated cash flows for the half year ended September 30, 2026 [Rs in Crore] Particulars For the half year ended September 30, 2026 (Unaudited) 335.40 145.49 (0.02) 93.07 (3.74) 1.30 (8.56) (0.36) (0.47) 4.40 For the half year ended September 30, 2025 (Unaudited) 333.77 139.59 0.03 98.23 (1.44) (1.17) - (0.33) (0.68) 4.00 A. Cash flow from operating activities Profit before tax Adjustments for : Depreciation and amortisation expense Net loss on property plant and equipment Finance costs Interest income Share of profit of an joint venture, net of tax Reversal of expected credit loss Deferred capital subsidy Net (gain) on sale of investments carried at fair value through profit or loss Share based payment expense Operating profit before working capital changes Changes in working capital: Adjustments for (increase) / decrease in operating assets: Trade receivables Inventories Financial assets Other assets Adjustments for increase / (decrease) in operating liabilities: Trade payables Financial liabilities Provisions Other liabilities Cash generated from operations Net income tax paid Net cash generated from operating activities (A) 566.51 57.02 (37.65) (5.34) (50.23) 126.10 5.88 27.69 (11.80) 678.18 (41.05) 572.00 (186.78) (73.85) (6.00) (54.77) 66.36 4.42 (13.50) (19.99) 287.89 (48.84) 637.13 239.05 B. Cash flow from investing activities Purchase of property, plant and equipment (including intangible assets, intangible assets under development, capital advances and capital creditors) (220.40) (116.87) Proceeds from sale of property plant and equipment (0.02) 0.09 Consideration paid towards business combination (Including transaction costs) (39.00) - Proceeds from redemption of mutual funds (net) 0.47 0.68 Proceeds from redemption of investment in bonds - 0.52 Investments in compulsory convertible debentures purchased from minority interest in subsidiary - (34.65) Loan given to joint venture (24.11) 0.14 Proceeds of bank balances not considered as cash and cash equivalents (3.48) 9.40 Interest received 1.88 1.44 Net cash used in investing activities (B) (284.66) (139.25) C. Cash flow from financing activities Proceeds from long term borrowings 231.32 - Repayment of long term borrowings (149.58) (143.23) Proceeds/ (repayment) from short term borrowings (net) (9.62) 55.94 Interest paid (144.15) (152.88) Payment for lease liability (including interest) (8.56) (6.38) Proceeds from issue of equity share capital (Employee stock options plan) 11.35 3.07 Dividend paid (99.88) - Net cash used in financing activities ( C) (169.12) (243.48) Net increase/(decrease) in cash and cash equivalents (A+B+C) 183.35 (143.68) Cash and cash equivalents at the beginning of the period 54.74 199.74 Cash and cash equivalents at end of the period 238.09 56.06
Page 8
Additional information pursuant to Regulation 52(4) of Securities and Exchange Board of India (Listing Obligation and Disclosure requirements) Regulations, 2015 as amended for the quarter and half year ended September 30, 2026 Consolidated For quarter ended For half year ended For year ended Particulars , September 30, • 2026 (Unaudited) June 30, 2026 (Unaudited) September 30, 2025 (Unaudited) September 30, 2026 (Unaudited) September 30, 2025 (Unaudited) March 31, 2026 (Audited) Debt - Equity Ratio (in times) (Total Debt(including lease liabilities)/Total Equity) 0.59 0.64 0.68 0.59 0.68 0.61 Debt Service Coverage Ratio (in times) (Profit after tax-Other income+ Depreciation and amortisation expense+Finance Costs+Committed Principal repayments made during the period for long term loans/Finance Costs +Committed Principal repayments made during the period for long term loans) 3.12 2.75 2.65 2.94 2.63 2.91 Interest service coverage ratio (in times) (Earnings before share of profit from joint venture, exceptional items, Interest and Tax/Finance Costs) 5.15 4.86 4.48 5.00 4.39 4.40 Outstanding redeemable preference shares (quantity and value) NA NA NA NA NA NA Capital redemption reserve/debenture redemption reserve (Rs in crore) 0.17 0.17 0.17 0.17 0.17 0.17 Net worth (Rs in crore) 4,141.57 3,944.22 3,503.48 4,141.57 3,503.48 3,895.66 Net profit after tax (Rs in crore) 187.14 143.32 134.47 330.46 259.57 647.51 Earnings per share Basic Diluted 13.26 13.25 10.28 10.26 8.82 8.81 23.54 23.53 17.49 17.46 45.33 45.26 Current Ratio (in times) (Current Assets/Current Liabilities) 0.67 0.60 0.91 0.67 0.91 0.74 Long term debt to working capital (in times) (Long-term borrowing+Lease liabilities including its current maturity)/Current Assets- Current liabilities (excluding current maturity) 3.10 4.59 11.36 3.10 11.36 5.13 Bad debts to account receivable ratio (in times) (Bad debts/Trade receivables) Nil Nil Nil Nil Nil Nil Current liability ratio (in times) (Current liabilities/Total liabilities) 0.78 0.77 0.42 0.78 0.42 0.60 Total debts to total assets (in times) (Total Debt (including lease liabilities)/Total Assets) 0.32 0.33 0.33 0.32 0.33 0.32 Debtors' turnover* (in times) (Sales/Trade receivables) 5.24 4.32 4.63 5.24 4.63 4.58 Inventory Turnover* (in times) (Cost of goods sold/Average Inventory) 1.98 1.93 2.21 1.98 2.21 2.06 Operating margin percent (Earnings before share of profit/ (loss) from joint venture, exceptional items, Finance cost and Tax/Revenue from Operations) 26.80% 25.94% 28.01% 26.37% 27.52% 27.11% Net profit margin percent (Profit after tax/Revenue from Operations) 20.97% 16.41% 16.97% 18.72% 16.58% 20 69% *Quarterly ratios based on trailing twelve months values.
Page 9
Amit Bak Chairman and Managing Director DIN : 01250925 Place: Ahmedabad Date: October 26, 2026 Notes to Unaudited Consolidated Financial results 1 The above statement of Unaudited Consolidated Financial results ("the Statement") have been recommended by the Audit Committee and approved by the Board of Directors at their meetings held on October 26, 2026. 2 The Unaudited Consolidated Financial results of the Holding Company have been prepared in accordance with recognition and measurement principles laid down in the Indian Accounting Standards ('Ind AS') 34, Interim Financial Reporting (Ind AS 34) as prescribed under Section 133 of the Companies Act, 2013 ('the Act") and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 and Regulation 52 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 (as amended). 3 The Holding Company has issued and allotted 1,95,682 ordinary shares of Rs 1 each under the Company's Employee Stock Option Scheme 2021 for the half year ended September 30, 2026. 4 The Holding Company is primarily engaged in one business segment namely - "Pharmaceuticals" - as determined by the chief operating decision maker in accordance with Ind AS 108 - "Operating Segment". 5 (A) Exceptional items for the period ended September 30, 2026 comprise of settlement with customers for supply of products, which were launched at risk in earlier periods. The Company has recognised a write down of amounts due from such customers of Rs. 35.90 Crore (net of collections, provisions made in the past) as part of such settlement. (B) Effective from November 21, 2025, The Government of India has consolidated multiple existing labour legislations into a unified framework comprising four Labour Codes collectively referred to as the 'New Labour Codes'. The Holding Company has assessed the financial implications of these changes which has resulted in increase in gratuity liability and leave liability arising out of past service cost by Rs 17.24 Crores primarily arising due to change in definition of "wages" for employees and contract labours. The Holding Company has presented such incremental impact under "Exceptional Item" in the consolidated financial results for the year ended March 31, 2026. 6 For the Financial year ended March 31, 2026, the Holding Company has completed acquisition of the Branded Probiotics Business from Velbiom Probiotics Private Limited for a consideration of Rs 50 Crores on a slump sale basis. The acquisition was completed on March 31, 2026. The Holding Company is in the process of making final determination of fair values of identified assets and liabilities for the purpose of purchase price allocation. 7 Aprica Healthcare Limited (AHL), Eris Oaknet Healthcare Private Limited (EOHPL) and Eris Therapeutics Limited (ETL) had filed a Scheme of Arrangement ("Scheme") under Sections 230 - 232 read with Section 66 and other applicable provisions of the Companies Act, 2013, for the amalgamation of Aprica Healthcare Limited (AHL) and the demerger of the "Domestic Business" of Eris Oaknet Healthcare Private Limited (EOHPL) (collectively, the "Amalgamating Companies") into Eris Therapeutics Limited (ETL) (the "Resulting Company" and the "Amalgamated Company"). The Scheme was approved by the National Company Law Tribunal (NCLT) vide its order dated 24 September 2026, with an appointed date of 1 April 2025. The Scheme became effective on 22 October 2026 upon filing thereof with the Registrar of Companies. Pursuant to the Scheme of Arrangement, the business losses incurred by EOHPL in earlier years, on which deferred tax assets were not recognised in earlier years, can now be set off against the business profits of ETL and also amortisation of Brand assets have become tax deductible for ETL with effect from the Appointed date. Accordingly, the total tax effect in the consolidated financial results for the period ended 30 September 2026 is accounted for as current tax credit of Rs. 96 crores and deferred tax charge in Rs. 31 crores. The Goodwill amount from EOHPL and AHL in the consolidated financial statements as of 30 September 2026 has been adjusted for the deferred tax liabilities on brand assets amounting to Rs. 220 crores as on the Appointed date. For Eris Lifesciences Limited
Page 10
Walker Chandiok &Co LLP Walker Chandiok & Co LLP Block No. D/15th Floor, Cabin No. AS to A10 `West Gate4 Near YMCA Club, S.G Highway, Sarkhej Road, Ahmedabad-380015 Gujarat, India Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 and Regulation 52 read with Regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) To the Board of Directors of Eris Lifesciences Limited 1. We have reviewed the accompanying statement of standalone unaudited financial results (`the Statement') of Eris Lifesciences Limited (`the Company') for the quarter ended 30 September 2026 and the year to date results for the period 1 April 2026 to 30 September 2026 being submitted by the Company pursuant to the requirements of Regulation 33 and Regulation 52 read with Regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (listing Regulations'). 2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (`lnd AS 34'), prescribed under section 133 of the Companies Act, 2013 (`the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 and Regulation 52 read with Regulation 63 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. Chartered Accountants Offices in Ahmedabad, Bengaluru, Chandigarh, Chennai, Dehradun, Goa, Gurugrarn, Hyderabad, Indore, Kochi, Kolkata, Mumbai, New Delhi, Noida and Pune Walker Chandiok & Co LLP is registered with limited liability with identification number MC- 2085 and has its registered office at L-41, Connaught Circus, Outer Circle, New Delhi, 110001, India
Page 11
Walker Chandiok &Co LLP 4. Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 and Regulation 52 read with Regulation 63 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. For Walker Chandiok & Co LLP Chartered Accountants Firm's Registration No.: 001076N/N500013 Ashish Gupta Digitally signed by Ashish Gupta Date: 2026.10.26 13:11:43 +05'30' Ashish Gupta Partner Membership No.: 504662 UDIN: 26504662BRDUMC1900 Place: New Delhi Date: 26 October 2026 Chartered Accountants
Page 12
• 11.114TICt• FROST & SULLIVAN list Practices-20I3 Excellence Awards-2013 Eris Eris Lifesciences Limited MOH aill Business today/YES bank ent of Unaudited Standalone Financial Results for the Quarter and Half Year Ended September 30, 2026 (Rs. In Crore except per share data] Sr, No. Particulars For quarter ended For half year ended For year ended September 30, 2026 (Unaudited) June 30, 2026 (Unaudited) September 30, 2025 (Unaudited) September 30, 2026 (Unaudited) September 30, 2025 (Unaudited) March 31, 2026 (Audited) 1 Income Revenue from Operations Sale of products 472.46 433.81 637.58 906.27 1,205.48 1,779.77 Other operating income 9.78 10.18 12.92 19.97 23.66 41.97 Total Revenue from Operations 482.24 443.99 650.50 926.24 1,229.14 1,821.74 Other Income 19.24 26.38 23.59 45.62 46.27 98.31 Total Income 501.48 470.37 674.09 971.86 1,275.41 1,920.05 2 Expenses Cost of materials consumed 18.74 19.99 20.29 38.73 44.41 83.99 Purchase of stock-in-trade 141.62 128.10 134.83 269.72 241.52 478.22 Changes in inventories of finished goods, stock-in-trade and work-in- progress (12.28) 12.72 42.27 0.44 92.98 64.49 Employee benefits expense 82.01 90.84 85.42 172.85 179.20 340.62 Finance costs 42.06 42.16 46.50 84.22 91.64 179.54 Depreciation and amortisation expense 40.88 39.98 39.30 80.86 76.90 154.38 Other expenses 69.04 72.44 70.81 141.48 157.83 242.09 Total expenses 382.07 406.23 439.42 788.30 884.48 1,543.33 3 Profit before exceptional items and tax for the period / year(1-2) 119.41 64.14 234.67 183.56 390.93 376.72 4 Exceptional items (Refer note 4) 35.90 - - 35.90 - 14.67 5 Profit before tax for the period / year (3-4) 83.51 64.14 234.67 147.66 390.93 362.05 6 Tax expense Current tax 13.85 10.23 40.91 24.08 68.08 60.96 Deferred tax (59.49) 5.61 44.19 (53.88) 73.29 57.04 Total tax expense (45.64) 15.84 85.10 (29.80) 141.37 118.00 7 Net profit for the period / year (5-6) 129.15 48.30 149.57 177.46 249.56 244.05 8 Other Comprehensive income/ (loss) Items that will not be reclassified to profit or (loss) Re-measurement gains / (losses) on defined benefit plans 0.17 0.16 (0.77) 0.33 (1.54) 0.65 Income tax effect (0.04) (0.04) 0.27 (0.08) 0.54 0.04 Net movement on effective portion of cash flow hedges (0.94) - (0.94) - - Income tax effect 0.24 0.24 - Other Comprehensive Income/(loss) for the period / year, net of tax (0.57) 0.12 (0.50) (0.45) (1.00) 0.69 9 Total Comprehensive Income for the period / year (7+8) 128.58 48.42 149.07 177.01 248.56 244.74 10 Paid Up Equity Share Capital (Face Value of Rs 1 each) 13.87 13.86 13.62 13.87 13.62 13.8.5 11 Other Equity 3,181.61 12 Earnings Per Share (of Rs 1 each) (not annualised) : Basic 9.32 3.49 10.98 12.81 18.32 17.86 Diluted 9.31 3.48 10.96 12.80 18.29 17.83 Registered & Corporate Office: Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad - 380054 Phone: +91-79-69661000/1001 - Email: eris@erislifesciences.com - Web Site: www.eris.co.in CIN: L24232GJ2007PLC049867
Page 13
Statement of Standalone Assets and Liabilities as at September 30, 2026 [Rs in Crore] Particulars As at September 30, 2026 (Unaudited) As at March 31, 2026 (Audited) I. ASSETS ; Non Current Assets (a) Property, plant and equipment 103.71 99.64 (b) Right-of-use asset 22.01 24.55 (c) Goodwill 48.57 48.57 (d) Other intangible assets 2,112.38 2,179.79 (e) Intangible assets under development (f) Financial assets (i) Investments 6.05 1,414.06 - 1,414.05 (ii) Loans 551.55 456.51 (iii) Other financial asset 5.04 265.93 (g) Non current tax assets (net) 30.67 30.02 (h) Deferred tax assets (net) 280.39 226.36 (i) Other non-current assets 5.01 9.71 Total Non Current Assets 4,579.44 4,755.13 Current Assets (a) Inventories (b) Financial assets (i) Trade receivables 119.47 682.80 121.36 307.16 (ii) Cash and cash equivalents 3.19 25.18 (iii) Bank balances other than (H) above 2.70 2.58 (iv) Loans 249.67 500.34 (v) Other financial asset 40.50 2.98 (c) Other current assets 69.51 63.21 Total Current Assets 1,167.84 1,022.81 TOTAL- ASSETS 5,747.28 5,777.94 II. EQUITY AND LIABILITIES : Equity (a) Equity share capital 13.87 13.85 (b) Other equity 3,274.55 3,181.61 Total equity 3,288.42 3,195.46 Non Current Liabilities (a) Financial liabilities (i) Borrowings 186.60 797.62 (ii)Lease Liabilities 17.01 19.72 (b) Other non-current liabilities 0.37 0.48 (c) Provisions 46.93 46.93 Total Non Current Liabilities 250.91 864.75 Current Liabilities (a) Financial uauilitics (i) Borrowings 1,766.23 1,277.94 (H) Lease liabilities (iii) Trade payables 6.53 5.86 A) Total outstanding dues of micro enterprises and small enterprises 9.85 5.13 B) Total outstanding dues of creditors other than micro enterprises and small enterprises 291.38 214.22 (iv) Other financial liabilities 75.90 160.87 (b) Other current liabilities 19.05 25.91 (c) Provisions 30.97 27.80 (d) Income tax liabilities (net) 8.04 - Total Current liabilities 2,207.95 1,717.73 Total liabilities 2,458.86 2,582.48 TOTAL- EQUITY AND LIABILITIES 5,747.28 5,777.94
Page 14
Unaudited Statement of Standalone Cash Flows for the half year ended September 30, 2026 [Rs in Crore] For the half year ended Particulars September 30, 2026 September 30, 2025 (Unaudited) (Unaudited) A. Cash flow from operating activities Profit before tax 147.66 390.93 Adjustments for : Depreciation and amortisation expense 80.86 76.90 Net Loss on property plant and equipment (0.02) 0.03 Finance costs 84.22 91.64 Interest income (35.72) (35.88) Deferred capital subsidy (0.19) (0.23) Net (gain) on sale of investments carried at fair value through profit or loss (0.47) (0.68) Share based payment expense 4.40 4.00 Operating profit before working capital changes 280.74 526.71 Changes in working capital: Adjustments for (increase) / decrease in operating assets: Trade receivables (375.64) (434.31) Inventories 1.89 92.85 Financial assets (2.76) (0.31) Other assets (1.25) 39.52 Adjustments for increase / (decrease) in operating liabilities: Trade payables 81.86 34.09 Financial liabilities (0.31) 0.73 Provisions 3.50 (32.66) Other liabilities (6.68) (4.68) Cash (used in )/ generated from operations (18.65) 221.94 Net income tax paid (16.68) (25.55) Net cash flow from operating activities (A) (35.33) 196.39 B. Cash flow from investing activities Purchase of property, plant and equipment (including intangible assets, intangible assets under development, capital advances and capital creditors) (19.96) (22.37) Proceeds from sale of property plant and equipment - 0.09 Consideration paid towards business combination (39.00) - Proceeds from redemption of mutual funds (net) 0.47 0.68 Proceeds from redemption of investment in bonds - 0.51 Loan given to subsidiaries (350.98) (285.20) Loan repaid by subsidiaries 506.61 14.50 Loan given to others received back - (0.12) Proceeds of Bank balances not considered as cash and cash equivalents (0.12) 5.27 Interest income 0.55 0.68 Net cash from/ (used in) investing activities (B) 97.57 (285.96) C. Cash flow from financing activities Proceeds/(repayment) from short term borrowings (net) (119.28) 61.00 rroeeeua or long term evrrovvings we. 5c) Repayment of long term borrowings (117.14) (111.33) Consideration received from sales of investment in subsidiaries 261.29 209.75 Proceeds of borrowings from subsidiaries 94.46 9.10 Repayment of borrowings to subsidiaries (89.27) (10.92) Interest paid (130.41) (141.20) Payment for lease liability (including interest) (3.86) (3.82) Proceeds from issue of equity share capital (employee stock options plan) 11.36 3.07 Dividend paid (99.88) - Net cash flow from/ (used in) financing activities ( C) (84.23) 15.65 Net increase/(decrease) in cash and cash equivalents (A+B+C) (21.99) (73.92) Cash and cash equivalents at the beginning of the period 25.18 84.34 Cash and cash equivalents at end of the period 3.19 10.42
Page 15
Additional information pursuant to Regulation 52(4) of Securities and Exchange Board of India (Listing Obligation and Disclosure requirements) Regulations, 2015 as amended for the quarter and half year ended September 30, 2026 Particulars Standalone For quarter ended For half year ended Foryear ended March 31, 2025 (Audited) September 30, 2026 (Unaudited) June 30, 2026 (Unaudited) September 30, 2025 (Unaudited) September 30, 2026 (Unaudited) September 30, 2025 (Unaudited) Debt - Equity Ratio (in times) (Total Debt(including lease l(abilities)/Total Equity) 0.60 0.62 0.79 0.60 0.79 0.66 Debt Service Coverage Ratio (in times) (Profit after tax-Other income. Depreciation and amortisation expense+Finance Costs*Committed Principal repayments made during the quarter/ period for long term loans/Finance Costs +Committed Principal repayments made during the period for long term loans) 2.49 1.61 2.61 2.05 2.38 1.74 Interest service coverage ratio (in times) (Earnings before exceptional Items, Interest and Tax/Finance Costs) 3.84 2.52 6.05 3.10 3.18 5.27 Outstanding redeemable preference shares (quantity and value) NA NA NA NA NA NA Capital redemption reserve/debenture redemption reserve (Rs in crore) 0.17 0.17 0.17 0.17 0.17 0.17 Net worth (Rs in cram) 3,288.42 3,148.45 2,770.57 3,288.42 2,770.57 3,195.46 Net profit after tax (Rs In crore) 129.15 48.30 149.57 177.46 249.56 244.05 Earnings/ (loss) per share Basic Diluted 9.32 9.31 3.49 3.48 10.98 10.96 12.81 12.80 18.32 18.29 17.86 17.83 Current Ratio (In times) (Current Assets/Current Liabilities) 0.53 0.47 1.00 0.53 1.00 0.60 Long term debt to working capital (In times) (Long-term borrowing+Lease liabilities including its current maturity)/Current Assets Current liabilities (excluding current maturity) 4.07 5.11 7.52 4.07 7.52 11.28 Bad debts to account receivable ratio (in times) (Bad debts/ Trade receivables) Nil Nil Nil Nil Nil Nil Current liability ratio (in times) (Current liabilities/Total liabilities) 0.90 0.91 0.41 0.90 0.41 0.67 Total debts to total assets (In times) (Total Debt (including lease llabilities)/Total Assets) 0.34 0.36 0.40 0.34 0.40 0.36 Debtors' turnover" (In times) (Sales/ Trade receivables) 2.17 3.04 2.97 2.17 2.97 5.79 Inventory Turnover* (In times) (Cost of goods sold/Averags, Inventory) 5.11 5.29 4.89 5.11 4.89 4.01 Operating margin percent (Earnings before exceptional items Interest and Tax/Revenue from Operations) 33.48% 23.94% 43.22% 28.91% 39.26% 30.53% Net profit margin percent (Profit after tax/Revenue from Operations) 26.78% 10.88% 22.99% 19.16% 20.30% 13.40% °Quarterly ratios based on trailing twelve months values.
Page 16
For ris Lifesciences Limited, Amit Baks Chairman and Managing Director DIN : 01250925 Notes to unaudited Standalone Financial results 1 The above statement of unaudited Standalone Financial results ("the Statement") have been recommended by the Audit Committee and approved by the Board of Directors at their meetings held on October 26, 2026. 2 The Unaudited Standalone Financial results of the Company have been prepared in accordance with recognition and measurement principles laid down in the Indian Accounting Standards ('Ind AS') 34, Interim Financial Reporting (Ind AS 34) as prescribed under Section 133 of the Companies Act, 2013 ('the Act") and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 and Regulation 52 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 (as amended). 3 The Company has issued and allotted 1,95,682 ordinary shares of Rs 1 each under the Company's Employee Stock Option Scheme 2021 for the half year ended September 30, 2026. 4 (A) Exceptional items for the period ended September 30, 2026 comprise of settlement with customers for supply of products, which were launched at risk in earlier periods. The Company has recognised a write down of amounts due from such customers of Rs. 35.90 Crores (net of collections, provisions made in the past) as part of such settlement during the quarter and half year ended September 30, 2026. (B) Effective November 21, 2025, The Government of India has consolidated multiple existing labour legislations into a unified framework comprising four Labour Codes collectively referred to as the 'New Labour Codes'. The Company has assessed the financial implications of these changes which has resulted in increase in gratuity liability and leave liability arising out of past service cost by Rs 14.67 Crores primarily arising due to change in definition of "wages" for employees and contract labours. The Company has presented such incremental impact under "Exceptional Item" in the standalone financial results for the year ended March 31, 2026. 5 The Company is primarily engaged in one business segment namely - "Pharmaceuticals" - as determined by the chief operating decision maker in accordance with Ind AS 108 - "Operating Segment". 6 During the year ended March 31, 2026, the Company has completed acquisition of the Branded Probiotics Business from Velbiom Probiotics Private Limited for a consideration of Rs 50 Crores on a slump sale basis. The acquisition was completed on March 31, 2026. The Company is in the process of making final determination of fair values of identified assets and liabilities for the purpose of purchase price allocation. Place: Ahmedabad Date: October 26, 2026